Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719

Sionna Therapeutics, Inc.

2026-Q1 EPS reported -$0.60

Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.
Cash and equivalents $289.9M; expected to fund operations into 2028.
Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.
Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001628280-26-033870

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.